CLRB

Company Overview — What Does Cellectar Biosciences, Inc. Do?

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey. Cellectar Biosciences, Inc. (CLRB) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO James V. Caruso and employs approximately 10 people, headquartered in Madison, New Jersey. With a market capitalization of $11M, CLRB is one of the notable companies in the Healthcare sector.

Cellectar Biosciences, Inc. (CLRB) Stock Rating — Avoid (April 2026)

As of April 2026, Cellectar Biosciences, Inc. receives a Avoid rating with a composite score of 22.5/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.CLRB ranks #4,119 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Cellectar Biosciences, Inc. ranks #725 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CLRB Stock Price and 52-Week Range

Cellectar Biosciences, Inc. (CLRB) currently trades at $2.76. The stock lost $0.06 (2.1%) in the most recent trading session. The 52-week high for CLRB is $10.19, which means the stock is currently trading -72.9% from its annual peak. The 52-week low is $0.23, putting the stock 1100.0% above its annual trough. Recent trading volume was 6K shares, suggesting relatively thin trading activity.

Is CLRB Overvalued or Undervalued? — Valuation Analysis

Cellectar Biosciences, Inc. (CLRB) carries a value factor score of 8/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.37x, versus the sector average of 2.75x.

At current multiples, Cellectar Biosciences, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Cellectar Biosciences, Inc. Profitability — ROE, Margins, and Quality Score

Cellectar Biosciences, Inc. (CLRB) earns a quality factor score of 13/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -365.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -208.0% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CLRB Debt, Balance Sheet, and Financial Health

Cellectar Biosciences, Inc. has a debt-to-equity ratio of 59.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 2.96x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $13M.

CLRB has a beta of 9.83, meaning it is more volatile than the broader market — a $10,000 investment in CLRB would be expected to move 883.4% more than the S&P 500 on any given day. The stability factor score for Cellectar Biosciences, Inc. is 8/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Cellectar Biosciences, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Cellectar Biosciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-8.35. Net income for the quarter was $-31M. Operating income came in at $-31M.

In FY 2025, Cellectar Biosciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-8.35. Net income for the quarter was $-22M. Operating income came in at $-23M.

In Q3 2025, Cellectar Biosciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.41. Net income for the quarter was $-4M. Operating income came in at $-5M.

In Q2 2025, Cellectar Biosciences, Inc. reported revenue of $0 and earnings per share (EPS) of $-3.39. Net income for the quarter was $-5M. Operating income came in at $-6M.

Over the past 8 quarters, Cellectar Biosciences, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing CLRB stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CLRB Dividend Yield and Income Analysis

Cellectar Biosciences, Inc. (CLRB) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CLRB Momentum and Technical Analysis Profile

Cellectar Biosciences, Inc. (CLRB) has a momentum factor score of 51/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 13/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

CLRB vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Cellectar Biosciences, Inc. (CLRB) ranks #725 out of 838 stocks based on the Blank Capital composite score. This places CLRB in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CLRB against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CLRB vs S&P 500 (SPY) comparison to assess how Cellectar Biosciences, Inc. stacks up against the broader market across all factor dimensions.

CLRB Next Earnings Date

No upcoming earnings date has been announced for Cellectar Biosciences, Inc. (CLRB) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CLRB? — Investment Thesis Summary

The quantitative profile for Cellectar Biosciences, Inc. suggests caution. The quality score of 13/100 flags below-average profitability. The value score of 8/100 indicates premium valuation. High volatility (stability score 8/100) increases portfolio risk.

In summary, Cellectar Biosciences, Inc. (CLRB) earns a Avoid rating with a composite score of 22.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CLRB stock.

Related Resources for CLRB Investors

Explore more research and tools: CLRB vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CLRB head-to-head with peers: CLRB vs AZN, CLRB vs SLGL, CLRB vs VMD.